Dr. Daniel P. Petrylak spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Sunday, November 16, 2014 on “What the Urologist Needs to Know About Sequencing New Agents in CRPC.”

Keywords: urologist, sequencing, new agents, CRPC, immunotherapeutic, hormonal, cytotoxic, DNA damage.

How to cite: Petrylak, Daniel P. “What the Urologist Needs to Know About Sequencing New Agents in CRPC” Grand Rounds in Urology. July 16, 2015. Accessed Apr 2024. https://grandroundsinurology.com/prostate-cancer-daniel-p-petrylak-sequencing-new-agents-in-crpc/.

References

Andriole GL, McCullum-Hill C, Sandhu GS, et al. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013 Feb;189(2):486-92.
http://www.ncbi.nlm.nih.gov/pubmed/23253958

Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38.
http://www.ncbi.nlm.nih.gov/pubmed/25184630

Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010 May;21(5):315-24.
http://www.ncbi.nlm.nih.gov/pubmed/20138542

Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012 Nov;23(11):2943-7.
http://www.ncbi.nlm.nih.gov/pubmed/22771826

Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013 Jul;24(7):1802-7.
http://www.ncbi.nlm.nih.gov/pubmed/23585511

Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013 Apr 11;368(15):1458-9.
http://www.ncbi.nlm.nih.gov/pubmed/23574133

Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013 Jun;81(6):1297-302.
http://www.ncbi.nlm.nih.gov/pubmed/23582482

Small EJ, Raymond L, Gardner TA, et al. A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Cancer Res. 2015 Apr 29. pii: clincanres. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25925891